JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review

Expert Review of Clinical Pharmacology, Journal Year: 2023, Volume and Issue: 16(4), P. 279 - 295

Published: March 22, 2023

Numerous cutaneous dermatoses mediated by cytokines depend on the JAK STAT pathway for intracellular signaling. inhibitors form a useful therapeutic approach in treating these conditions. The literature effectiveness of treatment alopecia areata, vitiligo, atopic dermatitis, psoriasis and several other inflammatory autoimmune diseases is growing although very few conditions have sufficiently well performed studies to their credit and, barring indications, use rest remains empirical as yet.A search PubMed database was made using keywords Janus kinase OR AND dermatology with time duration limited last 5 years. Here, we review pathway, various which are currently used dermatology, being explored in.The pathology large number dermatological disorders via signal pathway. JAKinibs shown great promise refractory conventional therapy. Their current clinical based robust evidence (for some), anecdotal most dermatoses.

Language: Английский

---

Successful treatment of severe chronic cutaneous lupus with anifrolumab: A series of 6 cases

JAAD Case Reports, Journal Year: 2023, Volume and Issue: 37, P. 21 - 29

Published: May 4, 2023

Cutaneous lupus erythematosus (CLE) is a chronic autoimmune condition that encompasses several subtypes with varying morphologies but shared pathogenesis and cytokine signature.1,2 CLE often isolated to the skin; an additional 70% 80% of patients systemic (SLE) suffer from during their disease course.3,4 Given its potential for permanent scarring dyspigmentation, carries significant negative impact on quality life.5,6 Management has traditionally consisted preventive measures alongside combinations topical immunosuppressive therapies.

Language: Английский

---

Characterization of Clinicopathological Features and Autoantibody Profiles in Patients with Cutaneous Lupus Erythematous: A Single-Center Retrospective Study

American Journal of Clinical Dermatology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 19, 2025

Language: Английский

---

A Review of the Potential Benefits of Herbal Medicines, Small Molecules of Natural Sources, and Supplements for Health Promotion in Lupus Conditions

Life, Journal Year: 2023, Volume and Issue: 13(7), P. 1589 - 1589

Published: July 19, 2023

The Latin word lupus, meaning wolf, was in the medical literature prior to 1200s describe skin lesions that devour flesh, and resources available physicians help people were limited. present text reviews ethnobotanical pharmacological aspects of medicinal plants purified molecules from natural sources with efficacy against lupus conditions. Among these are artemisinin its derivatives, antroquinonol, baicalin, curcumin, emodin, mangiferin, salvianolic acid A, triptolide, total glycosides paeony (TGP), other supplements such as fatty acids vitamins. In addition, plants, herbal remedies, mushrooms, fungi have been investigated for their effects on different conditions through clinical trials, vivo, vitro, or silico studies reviewed. A special emphasis placed active phytochemicals, mechanisms action. This review can be helpful researchers designing new goal-oriented studies. It also practitioners gain insight into recent updates might patients suffering

Language: Английский

---

Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety

Medicina, Journal Year: 2022, Volume and Issue: 59(1), P. 56 - 56

Published: Dec. 27, 2022

The pharmacological treatment of systemic lupus erythematosus (SLE) aims to decrease disease activity, progression, compromise, and mortality. Among the alternatives, there are chemically synthesized drugs whose efficacy has been evaluated, but which have potential generate adverse events that may compromise adherence response treatment. Therapy selection monitoring will depend on patient characteristics safety profile each drug. aim this review is provide a comprehensive understanding most important synthetic used in SLE, including current options (mycophenolate mofetil, azathioprine, cyclophosphamide), their mechanism action, efficacy, safety, and, importantly, parameters should be considered while receiving pharmacotherapy.

Language: Английский

---

Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials

Expert Opinion on Emerging Drugs, Journal Year: 2023, Volume and Issue: 28(4), P. 257 - 273

Published: Oct. 2, 2023

ABSTRACTIntroduction Cutaneous lupus erythematosus (CLE) is an autoimmune disease that clinically heterogenous and may occur with or without the presence of systemic (SLE). While existing on a spectrum, CLE SLE present differences in their underlying pathogenesis therapeutic responses. No new therapies have been approved recent decades by U.S. Food Drug Administration for CLE, although frequently refractory to conventional therapies. There unmet need develop effective drugs as it significantly impacts patients' quality life leave irreversible disfiguring damage.Areas covered This review provides update latest phase 2 3 clinical trials performed using skin-specific outcome measures. Emergent are presented alongside mechanism action translational studies permitted identification critical targets among immune cells and/or pathways involved CLE.Expert opinion literature has few targeting type I interferon, its downstream signaling plasmacytoid dendritic shown promising results. Further research required long-awaited therapies, this highlights importance implementing dedicated fill current gap therapeutics.KEYWORDS: Anifrolumabcutaneous erythematosusdaxdilimabIberdomideinterferon IJAK inhibitorslitifilimabplasmacytoid Declaration interestV P Werth grants from Celgene, Janssen, Pfizer, Biogen, Gilead, Corbus Pharmaceuticals, Genentech, AstraZeneca, Viela, Syntimmune, Amgen, Regeneron, Argenx, CSL Behring, Ventus, q32 Bio, BMS, Horizon consulted Lilly, Medscape, Nektar, Incyte, EMD Sorona, Principia, Crisalis, Viela Kwoya Kirin, AbbVie, Octapharma, GSK, Astra-Zeneca, Cugene, UCB, Corcept, Beacon Bioscience, Rome Horizon, Merck, Kezar, Sanofi, Bayer, Akari, Calyx, Cabaletta Bio. The University Pennsylvania owns copyright CLASI.The authors no other relevant affiliations financial involvement any organization entity interest conflict subject matter materials discussed manuscript apart those disclosed.Reviewer disclosuresPeer reviewers relationships disclose.Additional informationFundingThis was funded National Institutes Health-USA (NIH-USA) R01AR071653 (to V Werth), United States Department Veterans Affairs Merit Review BX005921-01 (Veterans Health Administration, Office Research Development Biomedical Laboratory Development, Werth).

Language: Английский

---

O acometimento cutâneo do Lúpus Eritematoso e as principais estratégias utilizadas para seu tratamento

Brazilian Journal of Health Review, Journal Year: 2024, Volume and Issue: 7(1), P. 640 - 650

Published: Jan. 9, 2024

O lúpus eritematoso é uma doença autoimune com manifestações clínicas diversas, sendo que o acometimento cutâneo pode se manifestar como condição exclusivamente de pele, (LEC), ou parte das várias apresentações do sistêmico (LES). As lesões cutâneas causadas pela podem ter um impacto significativo na qualidade vida dos pacientes, principalmente devido à sua persistência crônica e às sequelas desfigurantes resultar delas. Nesse contexto, as abordagens terapêuticas atuais beneficiar os porém persistem necessidades não atendidas, incluindo desenvolvimento medicamentos mais eficazes menos tóxicos. objetivo presente artigo revisar a literatura acerca principais estratégias utilizadas para seu tratamento. Realizou-se revisão integrativa partir bases dados PubMed, MEDLINE SciELO, mediante utilização descritores: “Cutaneous lupus erythematosus” erythematosus AND treatments”. Foram selecionados 18 artigos nos idiomas português, inglês espanhol, publicados no período 2018 2023. envolve condições complexas, influenciadas por múltiplos fatores genéticos ambientais. Em relação aos genéticos, destaca-se genes relacionados apoptose celular, migração leucócitos, via interferon tipo I, cascata complemento, apresentação antígenos produção anticorpos. Já em influências ambientais, evidencia-se exposição radiação ultravioleta (UVA UVB), consumo indutores tabagismo possíveis gatilhos. No tratamento, essencial adotar medidas gerais, fotoproteção suplementação vitamina D, além da abstinência ao tabagismo, caso esteja presente. A terapêutica medicamentosa tópicos, corticosteroides tópicos inibidores calcineurina, sistêmicos, retinoides antimaláricos, imunomoduladores, anti-inflamatórios imunossupressores. Ademais, existem terapias biológicas emergentes, visam células sistema imunológico moléculas pró-inflamatórias, possível citar Rituximabe, Belimumabe, BIIB059, Anifrolumabe, AMG 811, Baricitinibe Ustekinumabe integrantes estudos promissores. percepção digna estudo independente fundamental pacientes sofrem LEC sem LES associado, daqueles têm bom controle doença, mas enfrentam resistentes Dessa forma, compreensão aprofundada melhores melhoria diretrizes tratamento essa dermatológica.

---

Chronic hepatitis B in rheumatic diseases: issues of screening and reactivation of infection: A review

Terapevticheskii arkhiv, Journal Year: 2024, Volume and Issue: 96(5), P. 523 - 530

Published: June 3, 2024

Patients with rheumatic diseases infected hepatitis B virus (HBV) are difficult to manage not only due the presence of risk factors for development and rapid progression liver cirrhosis, but also likelihood reactivation this infection. Despite successes achieved in fight against HBV, cannot be completely defeated hidden forms disease, escaping field vision a rheumatologist an infectionist. Based on results analysis current publications, paper presents rationale complete immunological screening patients when prescribing antirheumatic therapy. The issues role COVID-19 exacerbation chronic viral B, antiviral prevention monitoring discussed, classification drugs according HBV is presented.

Language: Английский

---

A Retrospective Review of 22 patients on Anifrolumab in Refractory Cutaneous Lupus

SKIN The Journal of Cutaneous Medicine, Journal Year: 2024, Volume and Issue: 8(4), P. 1644 - 1653

Published: July 23, 2024

Cutaneous lupus erythematosus (CLE) is a heterogeneous disorder that can present alone as cutaneous disease or in conjunction with systemic (SLE). Despite CLE often being severe and worsening quality of life, there still no FDA approved drug for CLE. Anifrolumab, fully humanized IgG1κ monoclonal antibody, has become interest because its significant skin improvement the SLE trials. We performed retrospective chart review cohort twenty-four patients initiating anifrolumab infusion therapy from January to November 2022. Twenty-two were also identified having addition SLE. Chart occurred up August 21, 2023. Of twenty-two patients, thirteen (59%) able reduce stop either prednisone disease-modifying antirheumatic (DMARD). Specifically, eight (36%) completely stopped at least one DMARD. Notably sixteen (70%) started on (50%) discontinue completely. Seventeen (77%) had lesions by resolution rash, flares since initiation, repigmentation, hair regrowth, decrease erythema scale. Two total reviewed did not have clear evidence although likely related SLE, therefore included data analysis are represented Table 2. The burden, ability other therapies, overall tolerability makes it promising those

Language: Английский

---

Systemic lupus erythematosus is a risk factor for having multiple subtypes of cutaneous lupus erythematosus

Lupus, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 21, 2024

Background Patients with cutaneous lupus erythematosus (CLE) can present one or multiple different subtypes of CLE. There is limited understanding the prevalence and associated risk factors for having CLE subtype diagnoses. Objective This study characterized frequency subtypes. Methods was a cross-sectional 319 patients enrolled in University Texas Southwestern Cutaneous Lupus Registry seen outpatient dermatology clinics at Medical Center Parkland Health from January 1, 2009 to December 31, 2021. Demographic clinical information collected each subject compared using univariate multivariable logistic regression analyses. Results 59 subjects (18.5%) were diagnosed two more Univariate analyses identified statistically significant differences rates systemic (SLE) diagnosis, history positive anti-nuclear antibody, arthritis, renal disorder, serositis In analysis, SLE diagnosis found be significant. Conclusions Our showed that almost out five have subtypes, being factor. Clinicians monitor developing account manifestations laboratory abnormalities SLE.

Language: Английский

---